Global Health Collaborative Uganda
  • Home
  • Who We Are
    • Our Mission
    • Our History
    • MUST & MRRH leadership
    • MUST-MGH Global Health staff
    • Our Partners
  • Our Work
    • Research & Innovation
      • Health Families
      • META
      • OpenSMS
      • REVAMP
      • SASH
      • SBI
      • UPIM
      • Extend
    • Global Partnerships
    • Core Infrastructure
  • Events
  • Stories from the field
    • combatting barriers to care in rural uganda
    • national nursing conference in uganda
    • out-of-the-box solutions for HIV/AIDS treatment in uganda
    • studying the barriers to antimalarial bednet use in uganda
  • Visitors
    • visitor information
    • visitor FAQ
  • Contact Us
 

Resistance Testing Versus Adherence Support for Management of Patients with Virologic Failure on First-Line Antiretroviral Therapy


REVAMP study is an open-label randomized controlled trial being conducted in Uganda and South Africa. It enrolls people living with HIV who have virologic failure on first line antiretroviral therapy and randomizes them to standard of care or immediate HIV resistance testing. The overarching goal of the study is to assess the efficacy, measured by viral resuppression, and cost-effectiveness of adding routine resistance testing to the management first-line treatment failure in sub-Saharan Africa.

Principle Investigators: Dr. Mark Siedner (MGH) and Dr. Bosco Bwana Mwebesa (MUST)

GHC Facebook

↑
Forum